Business Wire

Type One Energy Issues First Realistic, Unified Fusion Power Plant Design Basis

27.3.2025 16:28:00 CET | Business Wire | Press release

Share

Type One Energy announced today publication of the world’s first comprehensive, self-consistent, and robust physics basis, with conservative design margins, for a practical fusion pilot power plant. This physics basis is presented in a series of seven peer-reviewed scientific papers in a special issue of the prestigious Journal of Plasma Physics (JPP). They serve as the foundation for the company’s first Infinity Two stellarator fusion power plant project, which Type One Energy is developing for the Tennessee Valley Authority (TVA) utility in the U.S.

The Infinity Two fusion pilot power plant physics design basis realistically considers, for the first time, the complex relationship between competing requirements for plasma performance, power plant startup, construction logistics, reliability, and economics utilizing actual power plant operating experience. This Infinity Two baseline physics solution makes use of the inherently favorable operating characteristics of highly optimized stellarator fusion technology using modular superconducting magnets, as was so successfully proven on the W7-X science machine in Germany.

“Why are we the first private fusion company with an agreement to develop a potential fusion power plant project for an energy utility? Because we have a design anchored in reality,” said Christofer Mowry, CEO of Type One Energy. “The physics basis for Infinity Two is grounded in the knowledge of what is required for application to, and performance in, the demanding environment of reliable electrical generation for the power grid. We have an organization that understands this isn’t about designing a science project.”

Led by Chris Hegna, widely recognized as a leading theorist in modern stellarators, Type One Energy performed high-fidelity computational plasma physics analyses to substantially reduce the risk of meeting Infinity Two power plant functional and performance requirements. This unique and transformational achievement is the result of a global development program led by the Type One Energy plasma physics and stellarator engineering organization, with significant contributions from a broad coalition of scientists from national laboratories and universities around the world. The company made use of a spectrum of high-performance computing facilities, including access to the highest-performance U.S. Department of Energy supercomputers such as the exascale Frontier machine at Oak Ridge National Laboratory (ORNL), to perform its stellarator physics simulations.

“We committed to this ambitious fusion commercialization milestone two years ago and today we delivered,” said John Canik, Chief Science and Engineering Officer for Type One Energy. “The team was able to efficiently develop deep plasma physics insights to inform the design of our Infinity Two stellarator, by taking advantage of our access to high performance computing resources. This enabled the Type One Energy team to demonstrate a realistic, integrated stellarator design that moves far beyond conventional thinking and concepts derived from more limited modeling capabilities.”

The consistent and robust physics solution for Infinity Two results in a deuterium-tritium (D-T) fueled, burning plasma stellarator with 800 MW of fusion power and delivers a nominal 350 MWe to the power grid. It is characterized by fusion plasma with resilient and stable behavior across a broad range of operating conditions, very low heat loss due to turbulent transport, as well as tolerable direct energy losses to the stellarator first wall. The Infinity Two stellarator has sufficient room for both adequately sized island divertors to exhaust helium ash and a blanket which provides appropriate shielding and tritium breeding. Type One Energy has high confidence that this essential physics solution provides a good baseline stellarator configuration for the Infinity Two fusion pilot power plant.

“The articles in this issue [of JPP] represent an important step towards a fusion reactor based on the stellarator concept. Thanks to decades of experiments and theoretical research, much of the latter published in JPP, it has become possible to lay out the physics basis for a stellarator power plant in considerable detail,” said Per Helander, head of Stellarator Theory Division at the Max Planck Institute for Plasma Physics. “JPP is very happy to publish this series of papers from Type One Energy, where this has been accomplished in a way that sets new standards for the fidelity and confidence level in this context.”

Important to successful fusion power plant commercialization, this stellarator configuration has enabled Type One Energy to architect a maintenance solution which supports good power plant Capacity Factors (CF) and associated Levelized Cost of Electricity (LCOE). It also supports favorable regulatory requirements for component manufacturing and power plant construction methods essential to achieving a reasonable Over-Night Cost (ONC) for Infinity Two.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327324853/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye